SCLXW:NSD-Scilex Holding Company (USD)

COMMON STOCK | Drug Manufacturers - General |

Last Closing

USD 0.2575

Change

0.00 (0.00)%

Market Cap

N/A

Volume

28.00

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-01-16 )

Largest Industry Peers for Drug Manufacturers - General

Symbol Name Price(Change) Market Cap
AZN AstraZeneca PLC ADR

+1.23 (+1.87%)

USD 202.63B
AMGN Amgen Inc

+0.49 (+0.18%)

USD 141.18B
SNY Sanofi ADR

+1.37 (+2.77%)

USD 124.51B
GILD Gilead Sciences Inc

-0.73 (-0.79%)

USD 114.51B
BIIB Biogen Inc

+0.23 (+0.16%)

USD 22.18B
GRFS Grifols SA ADR

-0.23 (-3.08%)

USD 7.13B
AMRN Amarin Corporation PLC

-0.01 (-1.86%)

USD 0.18B
MIRA MIRA Pharmaceuticals, Inc. Com..

+0.01 (+0.84%)

USD 0.02B
SCLX Scilex Holding Company

+0.02 (+5.25%)

N/A

ETFs Containing SCLXW

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - General) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 22.62% 100% F 94% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 22.62% 100% F 94% A
Trailing 12 Months  
Capital Gain -35.64% 40% F 23% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -35.64% 40% F 22% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -23.40% 20% F 10% F
Dividend Return -23.40% 20% F 10% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 44.57% 20% F 43% F
Risk Adjusted Return -52.51% 30% F 13% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector